About Wegovy HD (semaglutide) injection 7.2 mg The FDA approval of Wegovy HD is based on the results of the STEP UP program, which included the phase 3 STEP UP clinical trial, which was a 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of once-weekly semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention
McInnes, L., Healy, J
Weight changes can sometimes unmask or worsen underlying thyroid conditions
For example, people with autoimmune diseases might have a higher risk of drug allergies
Trimboli P, Ossola N, Torre A, Mongelli F, Quarenghi M, Camponovo C, Lucchini B, Rotondi M, Ruinelli L, Garofalo F